Abstract     Description     Claims     Drawing  

CA2924360A1   [0006] 
WO2017222362A1   [0007] 

Nuclear Medicine and Biology   [0007] 
J Nucl Med   [0008] 
Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases   [0047] 
Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA)   [0047] 
Design, synthesis, and preclinical evaluation of prostate-specific membrane antigen targeted 99mTc-radioimaging agents   [0047] 
99mTc-labeling and evaluation of a HYNIC modified small-molecular inhibitor of prostate-specific membrane antigen   [0047] 
Clinical translation of a PSMA inhibitor for 99mTc-based SPECT   [0047] 
Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer   [0047] 
Fmoc Solid Phase Peptide Synthesis   [0047] 
COMU: A third generation of uranium-type coupling reagents   [0047] 
COMU: scope and limitations of the latest innovation in peptide acyl transfer reagents   [0047] 
Fmoc Solid Phase Peptide Synthesis   [0047]